Table 2. Risk of invasive breast cancer by ITGB3 Leu33Pro genotype.
|
Odds ratio (95% CI)
|
||||||
|---|---|---|---|---|---|---|
| Strata | Cases/controls | Noncarriers 33Leu/Leu | Heterozygotes 33Leu/Pro | Homozygotes 33Pro/Pro | Heterozygotes and homozygotes combined | |
| Age matched | 1 year | 1086/4647 | 1.0 | 1.0 (0.8–1.1) | 0.8 (0.5–1.2) | 1.0 (0.8–1.1) |
| 3 years | 1086/4715 | 1.0 | 1.0 (0.8–1.1) | 0.8 (0.5–1.3) | 1.0 (0.8–1.1) | |
| 5 years | 1088/4755 | 1.0 | 1.0 (0.8–1.1) | 0.8 (0.5–1.2) | 1.0 (0.8–1.1) | |
| 90% power to detecta | — | 1.3 | 1.8 | 1.3 | ||
| Multifactorially adjustedb | 1 year | 540/4397 | 1.0 | 1.1 (0.9–1.4) | 0.9 (0.5–1.6) | 1.1 (0.9–1.3) |
| 3 years | 540/4397 | 1.0 | 1.1 (0.9–1.4) | 1.0 (0.5–1.7) | 1.1 (0.9–1.3) | |
| 5 years | 540/4455 | 1.0 | 1.1 (0.9–1.4) | 0.9 (0.5–1.6) | 1.1 (0.9–1.3) | |
| 90% power to detecta | — | 1.4 | 2.1 | 1.4 | ||
ITGB3=integrin beta3; CI=confidence interval.
a
The smallest odds ratios our study (with 1-year age strata) could detect with 90% statistical power and P<0.05 on two-sided tests.
b
Including body mass index (continuous), alcohol consumption (continuous), parity (0 vs more childbirths), use of oral contraceptive pill (yes/no), menopausal status (pre- vs postmenopausal), use of hormone replacement therapy (yes/no).